Background: Concurrent chemoradiation is the current standard of treatment for patients with advanced unresectable head and neck squamous cell carcinoma (HNSCC). Due to the potent radiosensitizing properties of gemcitabine, we decided to assess its efficacy and toxicity with concurrent radiation in patients with advanced HNSCC.
Introduction
Head and neck cancer constitutes a heterogeneous group of malignancies which accounts for approximately 500 000 new cases worldwide each year, representing 3-5% of all cancers [1] . Radiation has been the standard treatment for locally advanced, unresectable cancer of the head and neck. These patients when treated with exclusive radiation have a 5-year survival rate of <25%, and most treatment failures occur locally or regionally within the irradiated fields [2] . Chemotherapy has been combined with radiation in an attempt to improve outcome; the most promising approach being the administration of chemotherapy concurrent with radiation [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . A number of randomized studies have shown improved results when radiation was combined with concurrent cytotoxic agents compared with radiation alone despite increased toxicity of the combined arm, notably hematological and mucosal toxicities, which limited the ability to deliver full doses of radiation or the chemotherapeutic agents [4-8, 11, 12] . Although most trials of concurrent chemoradiation have used cisplatin in combination with 5-fluorouracil (5-FU), there is at present no evidence that this combination performs better than cisplatin alone [13] ; thus, the optimal drugs, doses and schedules of concurrent chemotherapy and radiotherapy for head and neck cancer are not yet known.
Gemcitabine [2′,2′-difluoro-2′-deoxycytidine (dFdCyd)] is a synthetic pyrimidine antimetabolite that interferes with DNA synthesis by inhibiting ribonucleotide reductase, hence reducing deoxynucleotide pools, competes with deoxycytidine triphosphate (dCTP) for incorporation into elongating DNA strands and halts DNA polymerization [14] [15] [16] . Moreover, gemcitabine exerts anti-tumor activity in a number of murine solid tumors and human xenografts and frequently increases the levels of deoxycy-tidine kinase in tumor cells, a process that may enhance the ability of gemcitabine to increase the therapeutic ratio [17] [18] [19] . This drug, either alone or in combination with cisplatin, has shown activity against head and neck carcinoma [20] [21] [22] . Moreover, experimental data demonstrate that gemcitabine is among the radiosensitizers, one of the most potent in a number of cancer cell lines, including head and neck cancer cells [23] [24] [25] [26] [27] . In 1997, Eisbruch et al. reported their preliminary results of a phase I study evaluating low-dose gemcitabine concurrently with standard radiation [28] . At a starting dose of 300 mg/m 2 /week, they found a remarkably high tumor control rate, although excessive mucosal toxicity led them to reduce the dose. Based on these data, we decided to use a third of the initial dose used by Eisbruch et al.
(100 mg/mg 2 /week) in this study.
Patients and methods
Patients eligible for the study had locally advanced disease [stages III, IVa and IVb according to the International Union Against Cancer (UICC) classification], histologically proven and measurable squamous cell carcinoma of the head and neck, without evidence of distant metastases at the beginning of the study. Patients were included in the study if they had unresectable disease or refused surgery. Tumors were defined as unresectable when surgical resection was considered technically not feasible or surgical resection with clear margins was estimated to produce significant organ and/or function loss. Patients who had received prior chemotherapy were not excluded. Eligibility criteria included Karnofsky performance status score ≥70%, age 18-75 years, estimated life expectancy of >3 months, adequate liver function tests [bilirubin <1.5 mg/dl and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevated ≤3 × normal range], bone marrow reserve (hemoglobin >10 g/dl, leukocyte count >4000/dl, platelet count >100 000/dl) and renal function (serum creatinine ≤1.5 md/dl and creatinine clearance >60 ml/min). A complete history and physical examination were performed before treatment, including chest radiograph, head and neck computed tomography (CT) and direct endoscopy to assess tumor extent.
Chemotherapy
Gemcitabine was administered intravenously over 30 min once weekly, 1-2 h before radiation, for 7 consecutive weeks at 100 mg/m 2 , in the first 15 patients and at 50 mg/m 2 for the last 12 patients accrued. Dose reduction was decided after patient 15 died from presumed toxicity (gastric perforation) and as a recommendation of the Review Board.
Radiation therapy
Radiotherapy was delivered once daily, 5 days a week as a single 2 Gy fraction. The total dose administered to the macroscopic tumor and to potential sites of microscopic spread was 70 Gy, intended to be delivered over 7 weeks. Radiation was administered using standard lateral opposed 6 MV photon beams and an anterior low-neck field. CT-based treatment planning was performed to assure adequate target coverage and safety. The maximal dose to the spinal cord was restricted to 45 and 54 Gy to the brain stem and optic nerves, respectively.
Toxicity
Toxicity was evaluated weekly according to the World Health Organization (WHO) scoring system: any grade 4 toxicity warranted 1-week delay in the administration of both chemotherapy and radiation. Toxicities were recorded as the worst grade experienced by the patients during treatment.
Response criteria
Assessment of tumor response was performed 4-6 weeks after the end of treatment according to WHO criteria. Tumor response was evaluated by physical examination, head and neck CT and endoscopy with biopsies of the tumor bed.
Complete response (CR) was defined as the disappearance of all evidence of disease by physical examination, CT and direct endoscopy. Partial response (PR) status was defined as a reduction of ≥50% of the product of the longest perpendicular diameters of measurable disease, with no progression at other sites of disease and no appearance of new lesions. Patients were considered to have no response if they did not achieve PR status and did not show progressive disease. Tumor progression was considered if there was an increase of ≥25% in the product of the longest perpendicular diameters of tumor lesions, or the appearance of new ones.
Statistical analysis
Data were summarized using frequencies, percentages, means, standard deviations and ranges. Overall survival (OS) and progression-free survival (PFS) time were analyzed using the Kaplan-Meier method [29] .
Results

Patient population
From January 1997 to December 2001, 27 patients were enrolled. Patient and tumor characteristics are summarized in Tables 1 and  2 . All patients had squamous cell carcinoma and most tumors (93%) were well or moderately differentiated. All patients were staged as III (10 patients, 37%) or IV-a and IV-b (17 patients, 63%); no patient had IV-c disease. The most commonly involved primary sites were larynx in 12 patients (44%) and paranasal sinuses in 7 patients (26%). Sixteen patients (60%) had unresectable disease: the main reason for this was fixation or involvement of the carotid artery and/or trachea (nine patients); the remaining 11 patients either refused surgery or were believed to require extensive and morbid surgery. Radiotherapy was not previously delivered to any patient; moreover, two patients had previously received cisplatin-based chemotherapy without response.
Toxicity
All 27 patients were assessable for toxicity; acute toxicities were common but manageable (Table 3) . One death during chemoradiation was recorded-a gastric perforation 8 weeks after the initiation of treatment (gemcitabine 100 mg/m 2 ). Mucositis and nausea/vomiting were the most common acute and serious sideeffects; dysphagia and pain commonly were grade 2 ( Table 3) . Hematological toxicity was uncommon with grade 3-4 neutropenia occurring in 11% of patients; however, lymphopenia grades 3-4 was observed in 74% of patients. No events of thrombocytopenia and febrile neutropenia were recorded and no red blood cell transfusions were required. Allergic skin rash was observed in three patients, grade 1 radiodermatitis was observed in four patients and grade 2 in nine patients (Table 3) . Gastric feeding tubes were required in seven cases due to inability to maintain nutrition orally. Acute toxicity was manageable in most cases; however, after 15 patients were treated, the high incidence of grade 3-4 mucositis (11/15 patients), resulting in radiotherapy interruption and one toxic death, prompted us to lower the dose of gemcitabine to 50 mg/m 2 .
Radiation dose-intensity was maintained: the median radiation dose delivered was 70 Gy (40-80 Gy). Twenty-five (93%) patients received ≥80% of the prescribed total dose of radiotherapy and most of them underwent the 7-week combined treatment with no interruptions; however, in eight patients (29%) radiotherapy was delayed, due to mucositis, for between 2 and 6 weeks, although no difference in response rates or survival was observed among them. In contrast, chemotherapy dose intensity was ≥80%, 60-79% and <60% in 13 (48%), seven (26%) and seven (26%) patients, respectively.
Late toxicity consisted of mild and moderate xerostomy observed in 16 (59%) and seven patients (26%), respectively. The patient who died from a second primary tumor (papillary thyroid cancer) developed a symptomatic esophageal stricture; however, it should be stated that no objective evaluation of swallowing function was performed.
Response to treatment
Only one patient was not assessable for response due to early toxic death. Sixteen of 26 evaluable patients (61%) achieved a complete response confirmed by CT and direct endoscopy, PR was observed in seven (27%) cases, for an objective response rate of 88% [95% confidence intervals (CI) 0.70-0.96] and three patients had no response. The median duration of the response was 21 months (range 2-56). Four of 16 patients who had achieved CR relapsed, three locally and one with pulmonary metastases. All seven patients with evidence of PR and the three patients with no response progressed locoregionally. The mean time to relapse or progression was 13.6 months (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . There was no correlation of response with tumor grade, nodal status, stage or primary site.
Outcome
The median follow-up time was 13 months (range 6-62). PFS and OS are shown in Figure 1 . The median PFS was 7 months (range 0-56) and the median OS was 13 months (range 6-62). Local control was good, among the 16 patients with complete response, 13 (81%) remained free of local recurrent disease (recurrence at 8, 11 and 22 months). The only patient who devel- oped distant metastases was free of local and regional relapse for 11 months. Currently, at a maximum follow-up of 62 months (median 1), nine patients (33%) were still alive and free of disease. Eighteen patients have died: 14 of disease recurrence or progression (including the one toxic death), two from unrelated intercurrent illnesses and two from a second primary (soft-tissue sarcoma and thyroid cancer, respectively). There was no significant difference in PFS and OS according to primary tumor site, stage or nodal status; however, a trend towards better survival was observed for stage: 50% of stage III patients were alive at 36 months compared with 28% for those in stage IV. The only variable that demonstrated a statistically significant association with longer survival was the response: median survival time for patients with CR, PR and NR was 40, 9 and 5 months, respectively (P = 0.0001) (data not shown).
Discussion
Although concurrent chemoradiation has become the standard of care for advanced and/or unresectable head and neck carcinoma patients, the best drug and schedule of chemoradiation remains to be determined. This trial was designed to test the efficacy and toxicity of a regimen of weekly gemcitabine concurrent with radiation in a group of patients with advanced HNSCC. Most of the patients were stage IV and considered unresectable by the referring surgeon: 60% had fixation of the primary tumor to the cervical spine or invasion to the trachea or common carotid artery and nine of them had N2 or N3 nodes. Despite these unfavorable patient characteristics, this regimen showed an encouraging tumor response rate and acceptable survival results. The efficacy of this schedule of gemcitabine, in which less than one-tenth of the usual systemic dose was administered, confirms its potent radiosensitization effect, which is further supported from pharmacokinetic data from Eisbruch et al. showing that a dose as low as 50 mg/m 2 / week is able to achieve adequate intracellular concentrations of the active drug metabolite, dFdCTP [30] .
The results of this study in both efficacy and toxicity are comparable to those recently reported by Eisbruch et al. [30] , a chemoradiation trial in which gemcitabine was administered at 300 mg/m 2 ; however, due to late mucosal and pharyngeal toxicity, successive patient cohorts received de-escalated dose levels of gemcitabine at 150, 50 and 10 mg/m 2 . The most important finding emerging from that study was that the combination of radiotherapy and gemcitabine, even at doses 5% of those administered when the drug is used as a cytotoxic agent, produced a high response rate of 66-89% among the different cohorts. In our study, using gemcitabine at two dose levels (100 and 50 mg/m 2 ), we achieved an overall response rate of 88%. This slightly different response rate could stem from the fact that we accrued a significant number of patients with primary tumors of the paranasal sinuses, which may carry a poorer prognosis [31] .
A second trial, by Benasso et al. [32] , used the combination of cisplatin, gemcitabine and radiation therapy. In this study, the incidence and severity of toxicity led the authors to stop accrual after 14 patients were treated; the chemotherapy regimen used was based on typical 'systemic' doses of both cisplatin and gemcitabine, explaining the development of severe hematological toxicity and mucositis in >80% of patients. Despite the unacceptable toxicity profile, this combination demonstrated high activity and good local control; however, only 21% of patients received the planned dose of gemcitabine, which supports its use in HNSCC as a radiation sensitizer rather than as a cytotoxic agent.
Severe acute mucositis is the most frequent limiting toxicity in studies of chemoradiation for HNSCC. We observed a significant rate of grade 3-4 mucositis (74%); however, it is lower than the one observed in most novel and more aggressive chemoradiation schedules and comparable with most previously reported studies [6-8, 33, 34] . Because a toxic death occurred, we intended to decrease mucosal toxicity by reducing gemcitabine dose to 50 mg/m 2 , as Eisbruch et al. suggested [30] . The rationale for this reduction was the earlier development and longer duration of acute mucositis in the cohorts receiving gemcitabine 300 and 150 mg/m 2 as compared with the cohorts receiving 50 and 10 mg/m 2 , apparently with no negative effect on tissue radiosensitization. However, we observed no significant lessening of the toxicity profile or significant difference in response or local control with the lower dose. A possible explanation for this finding is that the concentration at which gemcitabine produces radiosensitization, and more specifically ribonucleotide reductase inhibition, is >1000-fold lower than the typical plasma concentrations of the drug, and there seems to be, in a phase I trial, no significant difference in plasma concentrations between 50, 150 and even 300 mg/m 2 [35] .
Most combined schedules of chemoradiation are associated with a high, sometimes unacceptable, systemic toxicity, particularly hematological toxicity, such as febrile neutropenia and sepsis [36, 37] . The most important theoretical advantage of using 'low' dose gemcitabine is maintaining a high response rate and radiosensitization with low systemic toxicity. In our study, and as also reported by Eisbruch et al. [30] , hematological toxicity was mild, severe neutropenia was found only in 11% of patients and no events of febrile neutropenia were recorded. Likewise, grade 3-4 thrombocytopenia was not observed and no red blood cell transfusions were required. On the other hand, despite mucosal toxicityinduced delays, radiotherapy dose intensity could be maintained. An interesting observation was the presence of severe lymphopenia observed in 74% of patients. Radiation-induced lymphopenia and its possible deleterious effect on cancer patients should be addressed in future studies; in this regard, recent work from our institution demonstrates long-term immune dysfunction after radiotherapy to the head and neck area [38] .
At a median follow-up of 13 months and a maximum of 62 months, the projected survival was 33%. Considering the advanced stage and poor prognosis of the enrolled patients, the concurrent use of radiotherapy and gemcitabine demonstrated an encouraging survival as compared to other chemoradiation trials, which range from 24% to 49% [39] . It is noteworthy that the low frequency of second primary neoplasms observed could be the result of the large proportion of patients with sinus carcinomas accrued, as this tumor type is characterized by its low ability to give rise to distant metastases.
In summary, gemcitabine at relatively low doses is a potent radiosensitizer effective in HNSCC patients; however, at the schedule used it produces a high incidence of mucositis and xerostomy. Further studies are needed to optimize the administration of gemcitabine with radiation. In particular, intensity-modulated radiation seems promising as it could improve the therapeutic index of this combination.
